Recursion PharmaceuticalsRXRX
RXRX
About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Employees: 500
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
102% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 6 (+0) [Q3]
2% less funds holding
Funds holding: 268 [Q2] → 263 (-5) [Q3]
10% less capital invested
Capital invested by funds: $1.9B [Q2] → $1.72B (-$182M) [Q3]
10% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 50
17.28% less ownership
Funds ownership: 110.22% [Q2] → 92.93% (-17.28%) [Q3]
42% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $19.8M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$11
82%
upside
Avg. target
$11
82%
upside
High target
$11
82%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Needham Gil Blum 21% 1-year accuracy 34 / 164 met price target | 82%upside $11 | Buy Reiterated | 11 Dec 2024 |
Financial journalist opinion
Based on 8 articles about RXRX published over the past 30 days
Positive
The Motley Fool
4 hours ago
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.
Positive
The Motley Fool
4 hours ago
1 Artificial Intelligence (AI) Stock That Could Soar in 2025
The artificial intelligence (AI) field has been grabbing many headlines on Wall Street in the past two years. Will this trend continue in 2025?
Neutral
GlobeNewsWire
21 hours ago
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 7,952,836 shares of its class A common stock in the aggregate to 230 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with a subsidiary of Recursion in connection with Recursion's acquisition of Exscientia plc and pursuant to Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
1 week ago
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The recent acquisition of Exscientia strengthens Recursion's pipeline and partnerships, potentially delivering up to $20 billion in milestone payments from collaborations with pharma giants. Despite unimpressive clinical trial results, the company's innovative platform and strategic partnerships justify a "Buy" rating for long-term, high-risk-tolerant investors.
Neutral
GlobeNewsWire
1 week ago
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.
Positive
Seeking Alpha
1 week ago
Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Recursion Pharmaceuticals, Inc. expects to meet with the FDA to discuss the potential of advancing REC-994 for the treatment of patients with cerebral cavernous malformation. REC-1245 is a CDK12-adjacent target being developed in a phase 1/2 study for the treatment of patients with biomarker-enriched solid tumors and lymphomas. Data from the phase 1/2 study, exploring the use of REC-1245 for the treatment of patients with biomarker-enriched solid tumors/lymphomas, is expected by the end of 2025 or 1st half of 2026.
Positive
MarketBeat
2 weeks ago
NVIDIA Invested in These 2 AI Stocks, Should You?
NVIDIA Co. NASDAQ: NVDA is the undisputed leader of the artificial intelligence (AI) revolution. The company envisioned an AI future over 12 years ago and began executing the blueprint for domination.
Positive
The Motley Fool
4 weeks ago
2 Innovative Stocks That Could Deliver Outsize Returns
2 Innovative Stocks That Could Deliver Outsize Returns
Neutral
GlobeNewsWire
1 month ago
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (Nasdaq: EXAI) ceased trading and will be delisted from Nasdaq.
Neutral
GlobeNewsWire
1 month ago
Recursion and Exscientia Shareholders Approve the Proposed Combination
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
Charts implemented using Lightweight Charts™